LNTH Stock Drops After-Hours As Curium's $7B Offer Comes In Below Market Value
Lantheus Holdings (LNTH) shares dropped 3% after-hours on reports of a $7B acquisition offer from Curium, valued at $102 per share upfront, below its $108.03 closing price. The deal includes $12.50 per share in contingent value rights, totaling $8B. No final agreement has been reached.
How this was made
The 30-second read
Why it matters
The disclosed offer is the first public detail of the transaction, setting a new price floor for LNTH.
Market read
New M&A rumor drives immediate after‑hours price action; traders should monitor for offer updates.
What to watch
Potential synergies and pipeline expansion could justify higher valuation beyond current offer.
Background
Lantheus Holdings develops diagnostic imaging agents; Curium is a CapVest‑backed nuclear medicine firm.
Ticker impact
After-hours price fell 3% as Curium's $7B acquisition offer priced below LNTH's market cap.
Further short pressure unless offer terms are revised upward.
Offer price $102 vs $108.03 close is a clear discount, prompting sell‑off.
Market effects
Radiopharma sector may see valuation pressure on peers if deal terms remain low.
US biotech market could see slight dip in related stocks.
Limited to niche nuclear medicine space.
Counterpoint
If Curium secures regulatory approval, premium could rise, making LNTH a buy on the dip.
Key entities
- companyLantheus Holdings Inc.
Radiopharmaceutical developer (ticker LNTH).
- companyCurium
Nuclear medicine company backed by CapVest Partners.
